Senior Vice President and Chief Medical Officer, Head of Development · IDEAYA Biosciences, Inc. (IDYA)

Julie Hambleton

A named executive officer of IDEAYA Biosciences in every fiscal year CompBrief holds from FY2018 to FY2019. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2019

$686,726

Salary $387,063Stock awards $0

FY2018: $797,642

2nd of 4 named executive officers at Ideaya Biosciences by FY2019 total.

4 named officers on file for IDEAYA Biosciences, FY2019

Julie Hambleton’s pay file — $29

  • 2 fiscal years of pay, line by line
  • IDYA’s disclosed peer group of 21 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how IDEAYA Biosciences’s whole pay program stands against its peers

  • IDEAYA Biosciences’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on IDYA→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 27, 2020 (DEF 14A).

Free

Get Julie Hambleton’s full pay file as a PDF — free

More than this page: up to 10 years of Julie’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Julie Hambleton compensation by year

IDEAYA Biosciences Summary Compensation Table · all 2 fiscal years held
In US dollars, as IDEAYA Biosciences reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2018FY2019
Salary$218,750$387,063
Bonus$0$0
Stock awards$0$0
Option awards$512,217$180,964
Non-equity incentive$65,625$108,500
Pension and deferred compensation$0$0
All other$1,050$10,200
Total$797,642$686,726

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: IDEAYA Biosciences, Inc. DEF 14A filed April 27, 2020, accession 0001564590-20-018814, and prior-year filings. Open the filing on EDGAR.

How this page was built: the IDEAYA Biosciences, Inc. filed document, accession 0001564590-20-018814. Every figure is read from that document and cited to the page and table it appears in. Filed April 27, 2020.

$798K
$687K
FY18
FY19
SalaryNon-equity incentiveOption awardsAll other

Equity holdings

unvested awards at FY2019 year-end
TypeUnvested unitsValue at year-endExercise price
Option87,712—$4.62
Option17,063—$11.08

Per the Outstanding Equity Awards at Fiscal Year-End table in IDEAYA Biosciences, Inc.'s FY2019 proxy; value at the fiscal year-end close, as the company printed it.

IDEAYA Biosciences’s named executive officers, FY2019

as the company reported each
Named executive officerRoleFY2019 total
Yujiro HataPresident and Chief Executive Officer$2,020,989
Julie Hambleton · this pageSenior Vice President and Chief Medical Officer, Head of Development$686,726
Michael DillonSenior Vice President and Chief Scientific Officer, Head of Research$670,780
Paul StoneSenior Vice President and Chief Financial Officer$613,014

The full IDEAYA Biosciences compensation record

free company brief

This page is one person within IDEAYA Biosciences's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the IDEAYA Biosciences proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are IDEAYA Biosciences's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Julie Hambleton's compensation dossier · One-time report. No refunds.